Home » News » Drug Sponsors » Medivir proceeds with a separation of the company’s operations

Medivir proceeds with a separation of the company’s operations

Wednesday, August 31, 2016

Medivir has announced that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.

The Board´s target timing is that a separation of Medivir’s operations into a dedicated research and development company and a commercial pharmaceutical company should be completed before Year-end. The existing operations would thus be conducted by two clearly focused, specialized companies.

Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!